<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124340</url>
  </required_header>
  <id_info>
    <org_study_id>BS BCG 0221</org_study_id>
    <nct_id>NCT05124340</nct_id>
  </id_info>
  <brief_title>Safety and Tuberculin Conversion Following BCG Vaccination</brief_title>
  <official_title>Safety and Tuberculin Conversion Following BCG Vaccine Vial (Bio Farma) Compared to Registered BCG Vaccine (Bio Farma) in Indonesian Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Soetomo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an bridging study, observer-blind, randomized, controlled prospective&#xD;
      intervention study. The primary objective is evaluate the safety of BCG Vaccine Vial (Bio&#xD;
      Farma).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is bridging study, observer blinded, comparative, randomized study. Approximately&#xD;
      220 subjects will be recruited, 110 subjects are the investigational arm and 110 subjects are&#xD;
      the active comparator arm.&#xD;
&#xD;
      The objective of the study is to evaluate the safety of BCG Vaccine Vial (Bio Farma), and&#xD;
      assess the the local and systemic reactions within 90 days after vaccination in each group,&#xD;
      and assess the tuberculin conversion in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Observer Blind : Investigational Product and Active Comparator are masking. Lot number is masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of BCG Vaccine Vial (Bio Farma)</measure>
    <time_frame>30 minutes after vaccination</time_frame>
    <description>Number and percentage of subject experience local reactions and systemic events occurring within 30 minutes after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the local and systemic reactions within 30 minutes, 24 hours, 48 hours, 72 hours, 7 days and 30 days after vaccination.</measure>
    <time_frame>30 days after vaccination</time_frame>
    <description>Number and percentage of subject experience ;ocal reactions and systemic events occurring within 24 hours, 48 hours, 72 hours, 7 days and 30 days after vaccination will be assessed per group with 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess local reactions at 60 days and 90 days after vaccination in each group.</measure>
    <time_frame>90 days after vaccination</time_frame>
    <description>Number and percentage of subject experience local reactions at 60 days and 90 days after vaccination will be assessed per group with 95% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess serious adverse events within 30 days after vaccinantion in each group.</measure>
    <time_frame>30 days</time_frame>
    <description>Number and percentage of subject experience Serious Adverse Events within 30 days after vaccination will be described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the tuberculin conversion in each group.</measure>
    <time_frame>2 days</time_frame>
    <description>Number and percentage of subject who have tuberculin conversion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>BCG Vaccination Reaction</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of BCG vial vaccine injected in right deltoid armintradermally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of BCG ampoule vaccine injected in right deltoid arm intradermally</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG vial vaccine</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG ampoule vaccine</intervention_name>
    <description>Intradermal injection</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy infant aged 0-1 month.&#xD;
&#xD;
          2. Infants born after 37-42 weeks of pregnancy.&#xD;
&#xD;
          3. Infant weighing 2500 gram or more at birth.&#xD;
&#xD;
          4. Father, mother or legally acceptable representative properly informed about the study&#xD;
             and having signed the informed consent form.&#xD;
&#xD;
          5. Parents will commit themselves to comply with the instructions of the investigator and&#xD;
             with the schedule of the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Child concomitantly enrolled or scheduled to be enrolled in another trial.&#xD;
&#xD;
          2. Evolving moderate or severe illness, especially infectious diseases or fever (axillary&#xD;
             temperature 37.5 celcius degrees).&#xD;
&#xD;
          3. Suspected of allergy to any component of the vaccines.&#xD;
&#xD;
          4. Newborn suspected of congenital or acquired immunodeficiency.&#xD;
&#xD;
          5. Received or plans to receive any treatment likely to alter the immune response&#xD;
             intravenous (immunoglobulins, blood-derived products or long term corticotherapy (&gt; 2&#xD;
             weeks)).&#xD;
&#xD;
          6. Received other vaccination with the exception of OPV and Hepatitis B vaccine.&#xD;
&#xD;
          7. Any abnormality or chronic disease which according to the investigator might interfere&#xD;
             with the assessment of the trial objectives.&#xD;
&#xD;
          8. Any skin disease such eczema generalisata other skin infection which makes difficult&#xD;
             the assessment of the local reactios.&#xD;
&#xD;
          9. Mothers with HbsAg and HIV positive (by rapid test)&#xD;
&#xD;
         10. Parents planning to move from the study area before the end of study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominicus Husada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RS DR Soetomo Surabaya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rini Mulia Sari, MD</last_name>
    <phone>+622033755</phone>
    <phone_ext>14102</phone_ext>
    <email>rini.mulia@biofarma.co.id</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCG Vaccine</keyword>
  <keyword>Safety of BCG Vaccine</keyword>
  <keyword>Tuberculin Conversion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

